Roche's Ronapreve Treatment for Covid-19 Approved by Japan
July 20 2021 - 1:45AM
Dow Jones News
By Giulia Petroni
Roche Holding AG on Tuesday said that Japan has approved
ronapreve for the treatment of patients with mild to moderate
Covid-19.
The Swiss pharmaceutical company said the approval is based on
results from the global Phase 3 REGN-COV 2067 study, which found
the antibody combination of casirivimab and imdevimab reduced
hospitalization or death by 70% in high-risk, nonhospitalized
patients.
"Ronapreve has been shown to improve survival in high-risk,
non-hospitalized Covid-19 patients by reducing the risk of
hospitalization and death," said Levi Garraway, Roche's chief
medical officer and head of global product development.
"In addition, its ability to retain activity against emerging
variants, including the Delta variant, has been demonstrated in
preclinical studies," Mr. Garraway said.
Outside Japan, the antibody combination has been authorized for
emergency use or temporary pandemic use in regions including in the
European Union, the U.S., India, Switzerland and Canada.
It is currently undergoing rolling review by the European
Medicines Agency.
Ronapreve is being jointly developed by Roche and Regeneron
Pharmaceuticals Inc.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
July 20, 2021 01:44 ET (05:44 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024